Clinical phase III open-labeled study of oral garenoxacin in patients with respiratory tract infection by penicillin-resistant Streptococcus pneumoniae

Japanese Journal of Chemotherapy

Volumn 55, Issue , 2007, Pages 185-193

  Kohno, Shigeru ^a   Watanabe, Akira ^b,b   Aoki, Nobuki ^c   Tateda, Kazuhiro ^d   Taniguchi, Hiroyuki ^e   Niki, Yoshihito ^f,h   Hirata, Yasunobu ^g  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c Shinrakuen Hospital   (Japan)

^d TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e TOSEI GENERAL HOSPITAL   (Japan)

^f KAWASAKI MEDICAL SCHOOL   (Japan)

^g UNIVERSITY OF TOKYO   (Japan)

^h SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

garenoxacin; penicillin resistant Streptococcus pneumoniae

Indexed keywords

AZITHROMYCIN; CEFDITOREN PIVOXIL; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; GARENOXACIN; LEVOFLOXACIN; PENICILLIN G; TELITHROMYCIN; TOSUFLOXACIN;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BRONCHITIS; CHRONIC RESPIRATORY TRACT DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; ECG ABNORMALITY; ERADICATION THERAPY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PENICILLIN RESISTANCE; PHASE 3 CLINICAL TRIAL; PNEUMONIA; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; SUPERINFECTION; UNSPECIFIED SIDE EFFECT;

EID: 35348987720     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: 10.11250/chemotherapy1995.55.Supplement1_185     Document Type: Article

References (2)

1. Takahata M, Mitsuyama J, Yamashiro Y, Yonezawa M, Araki H, Todo Y, et. al. : In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Antimicrob Agents Chemother 1999; 43 : 1077-84
2. Clinical and Laboratory Standards Institute. Per formance Standards for Antimicrobial Susceptibility Test; M100-S15, CLSI, 2005